- Aristocrat Group Corp. (ASCC)
- Big Tree Group, Inc. (BIGG)
- Blue Water Global Group, Inc. (BLUU)
- Boston Therapeutics, Inc. (BTHE)
- Calpian, Inc. (CLPI)
- CD International Enterprises, Inc. (CDII)
- Consorteum Holdings, Inc. (CSRH)
- Ecrypt Technologies, Inc. (ECRY)
- First Titan Corp. (FTTN)
- Global Payout, Inc. (GOHE)
- GlobalWise Investments, Inc. (GWIV)
- Innocent, Inc. (INCT)
- Intelimax Media, Inc. (IXMD)
- International Stem Cell Corp. (ISCO)
- Kallo, Inc. (KALO)
- Mabwe Minerals Inc. (MBMI)
- Max Sound Corp. (MAXD)
- Midwest Energy Emissions Corp. (MEEC)
- Nexus Enterprise Solutions, Inc. (NXES)
- OBJ Enterprises, Inc. (OBJE)
- On the Move Systems, Inc. (OMVS)
- OxySure Systems, Inc. (OXYS)
- Pan Global Corp. (PGLO)
- Raptor Resources Holdings Inc. (RRHI)
- Singlepoint, Inc. (SING)
- Sohm, Inc. (SHMN)
- Sparta Commercial Services, Inc. (SRCO)
- StreamTrack, Inc. (STTK)
- Victory Energy Corp. (VYEY)
- VistaGen Therapeutics Inc. (VSTA)
Cardium Therapeutics, Inc. (CXM)
Cardium Therapeutics, Inc. (CXM) is an asset-based, health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative products and businesses with the potential to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the newly-acquired To Go Brands nutraceutical supplement business.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia.
Cardium recently acquired To Go Brands® healthy nutraceutical supplement business with over 25 products being developed and sold by food, drug and mass channel retailers.
Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.
Christopher J. Reinhard
Chairman of the Board, Chief Executive Officer, President and Treasurer
Tyler M. Dylan-Hyde, PH.D. J.D.
Director, Chief Business Officer, General Counsel, Executive Vice President and Secretary
Dennis M. Mulroy, CPA
Chief Financial Officer
Gabor M. Rubanyi, M.D., PH.D.
Chief Scientific Officer
Robert L. Engler, M.D.
Chief Medical Advisor
Vice President, Business Development
Vice President - Manufacturing and Technical Operations
Lois A. Chandler
Vice President, Biologics Development
Vice President, Sales and Marketing